Compare MXCT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | LUNG |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.6M | 72.2M |
| IPO Year | 2021 | 2020 |
| Metric | MXCT | LUNG |
|---|---|---|
| Price | $0.72 | $1.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $5.50 | $5.38 |
| AVG Volume (30 Days) | ★ 982.6K | 727.7K |
| Earning Date | 03-24-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | $33,026,000.00 | ★ $90,497,000.00 |
| Revenue This Year | $18.61 | $2.48 |
| Revenue Next Year | $22.36 | $18.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.64 | $1.28 |
| 52 Week High | $2.96 | $7.05 |
| Indicator | MXCT | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 33.99 |
| Support Level | $0.64 | N/A |
| Resistance Level | $0.87 | $1.93 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 28.02 | 0.79 |
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.